abrocitinib 200 MG Oral Tablet

RxCUI: 2591489
RxNorm name: abrocitinib 200 MG Oral Tablet
Display name: abrocitinib 200 MG Oral Tablet
Full name: abrocitinib 200 MG Oral Tablet
Term type: SCD
Status: DailyMed mapping
Updated: 2026-06-04 23:38:55

RxNav Current And Historical NDCs#

RxNav current and historical NDC rows page 1 of 1 · 0 matching rows.

No records found.

UNII Substances#

UNII substance links page 1 of 1 · 0 matching rows.

No records found.

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 2 matching rows.

Brand, Generic, Manufacturer table
Brand	Generic	Manufacturer	SPL set ID	Effective date	Available safety fields	Join
CIBINQO	ABROCITINIB	U.S. Pharmaceuticals	16c12a56-4550-414b-ac9d-b785b41fea6b	2026-07-09	Boxed warning, Warnings, Adverse reactions	Exact identifier rxcui: 2591489
Cibinqo	ABROCITINIB	Pfizer Laboratories Div Pfizer Inc	3f6d6fcd-e9f9-42c8-bfa2-bb2cfc9ed258	2026-07-07	Boxed warning, Warnings, Adverse reactions	Exact identifier rxcui: 2591489

DailyMed RxNorm Mappings#

unique DailyMed labels mapped to this RxNorm concept page 1 of 1 · 2 matching rows.

Set ID, RxNorm mappings, Terms table
Set ID	RxNorm mappings	Terms	SPL version	Label	Effective
3f6d6fcd-e9f9-42c8-bfa2-bb2cfc9ed258	abrocitinib 200 MG Oral Tablet [PSN] · abrocitinib 200 MG Oral Tablet [SCD]	2	6	These highlights do not include all the information needed to use CIBINQO safely and effectively. See full prescribing information for CIBINQO. CIBINQO ® (abrocitinib) tablets, for oral use Initial U.S. Approval: 2022	20250109
16c12a56-4550-414b-ac9d-b785b41fea6b	abrocitinib 200 MG Oral Tablet [PSN] · abrocitinib 200 MG Oral Tablet [SCD]	2	4	These highlights do not include all the information needed to use CIBINQO safely and effectively. See full prescribing information for CIBINQO. CIBINQO ® (abrocitinib) tablets, for oral use Initial U.S. Approval: 2022	20250320